A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
But with Brukinsa and degraders looming, will fixed dosing make the difference?
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Enzomenib might be the most promising agent so far, on a cross-trial basis.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
